Calling all Alliance members and researchers! Register now for the Fall 2026 Group Meeting (Nov 4-6, 2026). Don't miss out on advancing cancer clinical trials together! ➡️ View registration and schedule at bit.ly/FallGroup2026 #Oncology #ClinicalTrials #CancerCare

Results from the Alliance RadiCaL (A031801) trial led by @DrRanaMcKay in @JCO_ASCO found that adding radium-223 does not improve time people with advanced kidney cancer went without serious bone complications. News - bit.ly/Radical26. Article - bit.ly/Radical-JCO

Now enrolling! The #REVITALIZE study (Alliance A221801) is testing laser therapy to relieve chronic vaginal dryness, a common but overlooked side effect of breast cancer treatment. 💗🧪 @maryam_lustberg #BCSM bit.ly/REVITALIZE2026 #bcsm #womenshealth #breastcancer

Now enrolling! @adawaksmd of @DanaFarber leads @ALLIANCE_org A012303 (ShortStop-HER2), a phase III study testing if less treatment after surgery is an option for people with early-stage HER2+ #breastcancer who had no cancer left after chemo + HER2 therapy. bit.ly/Alliance-A012303

#PRIMR specializes in patient-focused videos. The @ALLIANCE_org RadiCaL Study is investigating whether adding radium-223 to cabozantinib can prevent bone complications like pain or fractures in metastatic kidney cancer. Watch: primrmed.com/cancer-clinical… @DrRanaMcKay

Now enrolling! BCG (a bladder immunotherapy) is standard for non-muscle invasive bladder cancer. For cancer that returns after BCG, Alliance A032103 (GAIN) trial tests adding gemcitabine—a chemo drug—to BCG to prevent recurrence. Learn more: bit.ly/Alliance-GAIN-BCG #BladderCancer

Early detection, improved screening, and breakthrough clinical trials are transforming breast cancer care and supporting ~4 million survivors nationwide. 🎗️ Learn about the Alliance’s current breast cancer trials: bit.ly/Breast2026 #BreastCancerAwareness #clinicaltrials

Calling all Alliance members and researchers! Register now for the Fall 2026 Group Meeting (Nov 4-6, 2026). Don't miss out on advancing cancer clinical trials together! ➡️ View registration and schedule at bit.ly/FallGroup2026 #Oncology #ClinicalTrials #CancerCare

A 3-week postmastectomy radiation schedule is as safe & effective as the standard 5-week course for breast cancer patients undergoing reconstruction, according the RT CHARM trial (Alliance A221505) in @JCO_ASCO News:bit.ly/RT-CHARM Article: bit.ly/RT-CHARM-JCO #BCSM

New lung cancer trial open 🧪🫁 Alliance A082402 is studying if targeted post op radiation (I² PORT) can reduce recurrence in high risk #NSCLC patients after surgery while limiting side effects. Learn more bit.ly/I-PORT-Trial. #LungCancer #ClinicalTrials #RadiationTherapy

Late-breaking news from #ASTRO26: @ALLIANCE_org Phase III trial (A071801) finds 3-5 sessions of radiosurgery after surgery for large brain metastases outperforms single-session treatment in reducing local recurrence and boosting survival. @PDBrownOnc bit.ly/ASTRO26 #NCI

Now enrolling! Jennifer Ligibel MD of @DFCI_BreastOnc and Kathryn Schmitz PhD of @UPMCHillmanCC lead Alliance A222302 studying the feasibility of a telehealth exercise program for cancer patients with the goal of reducing fatigue and disability. bit.ly/DEFEND-trial #NCI

Now enrolling! The phase III HOPE study (A222301) led by Anurag Singh, MD of @RoswellPark is assessing whether high-dose gabapentin reduces opioid use in patients with oral mucositis during chemoradiation for head and neck cancer. Learn more: bit.ly/Alliance-A222301

A 3-week postmastectomy radiation course is as safe & effective as the standard 5-week course for breast cancer patients undergoing reconstruction, according RT CHARM trial (Alliance A221505) published in @JCO_ASCO News:bit.ly/RT-CHARM Article: bit.ly/RT-CHARM-JCO

Dr. Ugonma Chukwueke of @DanaFarber leads a new Alliance trial exploring if adding a targeted medicine called vorasidenib to the usual treatment can help people with newly diagnosed IDH mutated grade 3 astrocytoma, a type of brain cancer. bit.ly/Brain2026 #clinicaltrials

News from #ASTRO26: Fractionated radiosurgery reduces cancer recurrence after surgery for large brain metastases Phase 3 trial finds three to five radiation treatments improved control at the surgical site compared with a single treatment, without significantly increasing side effects. As seen in @GoHealio, HealthDay News, @cure_today & more. Presented by Ayal A. Aizer, MD. Learn more: bit.ly/4sf0ynx @PDBrownOnc @AyalAizer @BrighamWomens @DanaFarber @harvardmed @MayoRadOnc @ALLIANCE_org

NOW ENROLLING: Led by Devon Noonan of @DukeU A211901 offers personalized text-message support to help rural cancer survivors quit smoking. No travel required—get guidance on smoking cessation directly on your phone. Study details: 🔗 bit.ly/Alliance-A211901 #SmokingCessation

Calling all Alliance members and researchers! Register now for the Fall 2026 Group Meeting (Nov 4-6, 2026). Don't miss out on advancing cancer clinical trials together! ➡️ View registration and schedule at bit.ly/FallGroup2026 #Oncology #ClinicalTrials #CancerCare

Early detection, improved screening, and breakthrough clinical trials are transforming breast cancer care and supporting ~4 million survivors nationwide. 🎗️ Learn about the Alliance’s current breast cancer trials: bit.ly/Breast2026 #BreastCancerAwareness #clinicaltrials

Now enrolling! @thomashopemd of @UCSFHospitals and Deaglan McHugh of @MSKCancerCenter lead Alliance A032304 (RECIPROCAL), a phase III study to optimize targeted radiation therapy to minimize side effects while preserving efficacy in prostate cancer bit.ly/AllianceA032304